Melvin Chua, Head of the Department of Head Neck and Thoracic Cancers, Division of Radiation Oncology at National Cancer Centre Singapore, shared on X/Twitter:
”EBVDNA is an archetypal liquid biopsy in endemic NPC Several trials+NRGHN001 Nancy Lee stratifies patients based on post-RT EBVDNA. We show that this is dynamic and time point matters! This is an important consideration for current and future trials designs!
We found that 2/3 of patients who were deemed to be EBVDNA+ at 0-2w post-RT actually cleared by 8-12w.
And the outcomes for this group is in fact comparable to the patients who were EBVDNA 0 at both time points.”
For the article click here.
Source: Melvin Chua/X